|
Apr 30
|
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
|
|
Apr 1
|
Dyadic International, Inc. (NASDAQ:DYAI) Q4 2023 Earnings Call Transcript
|
|
Apr 1
|
DYAI: Capital Raise to Accelerate Near Term Revenue Growth
|
|
Mar 29
|
Q4 2023 Dyadic International Inc Earnings Call
|
|
Mar 28
|
Dyadic Reports 2023 Full Year Results and Recent Company Progress
|
|
Mar 28
|
Dyadic Announces Change in Board and Management Leadership Roles
|
|
Mar 27
|
Dyadic to Attend Industry Events in April
|
|
Mar 26
|
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
|
|
Mar 21
|
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
|
|
Mar 14
|
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
|
|
Mar 11
|
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
|
|
Mar 11
|
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
|
|
Feb 13
|
Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing
|
|
Jan 22
|
Dyadic International, Inc Invites You to Join Us at The Microcap Conference
|
|
Nov 30
|
Dyadic Attends Investor Events in December
|
|
Nov 29
|
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
|
|
Nov 9
|
Dyadic International, Inc. (NASDAQ:DYAI) Q3 2023 Earnings Call Transcript
|
|
Nov 9
|
DYAI: Third Quarter Update
|
|
Nov 8
|
Dyadic International Inc (DYAI) Reports Decrease in Q3 Revenue and Net Loss Improvement ...
|
|
Nov 8
|
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
|